1. Health promotion and education, change of lifestyle: correct poor lifestyle and behavior through health promotion, refer to the treatment of metabolic syndrome (III), recommend moderate calorie restriction, obese adults need to reduce daily calorie intake by 2092-4184 KJ (500-1000 kcal); change diet components, recommend a balanced diet with low sugar and low fat, reduce the intake of sucrose-containing beverages and saturated fat and trans fat and increase dietary fiber; moderate aerobic exercise, more than 4 times a week and at least 150 min of cumulative exercise time. A moderate amount of aerobic exercise, more than 4 times a week with a total exercise time of at least 150 min, is usually required to have a certain degree of weight loss to benefit the rehabilitation of metabolic syndrome components including NAFLD. 2. Weight control and waist circumference reduction: NAFLD patients with combined obesity who fail to reduce their body weight by more than 5% in 6-12 months of lifestyle change are advised to use metformin, sibutramine, orlistat and other drugs for secondary intervention with caution. Unless there is liver failure, moderate to severe esophagogastric varices, patients with severe obesity may consider upper gastrointestinal bariatric surgery when pharmacological weight loss treatment is ineffective. abnormal liver enzyme profiles and liver histological damage in NAFLD patients usually improve significantly with weight loss, but the most effective weight loss measures as well as the safety of weight loss drugs and how to prevent weight rebound need to be further explored. 3. Improving IR and correcting metabolic disorders: Depending on clinical needs, relevant drugs can be used to treat metabolic risk factors and their comorbidities (I). Unless there is obvious liver damage (e.g. serum transaminases greater than 3 times the upper limit of normal), liver insufficiency or decompensated cirrhosis, patients with NAFLD can safely use angiotensin receptor blockers, insulin sensitizers (metformin, pioglitazone, rosiglitazone) and statins to lower blood pressure and prevent glucolipid metabolism disorders and atherosclerosis. However, the ameliorative effects of these drugs on abnormal liver enzyme profiles and liver histological lesions in patients with NAFLD have yet to be confirmed by further clinical trials. 4. Reduce additional blows to avoid aggravating liver damage (III): Patients with NAFLD, especially NASH, should avoid drastic weight loss, prohibit very low calorie diets and empty ileal short-circuit surgery for weight loss, avoid small intestinal bacterial overgrowth, avoid exposure to hepatotoxic substances, and use cautiously Use of Chinese and Western drugs and health care products that may have hepatotoxicity, and excessive alcohol consumption is strictly prohibited. 5, hepatoprotective anti-inflammatory drugs against hepatitis and fibrosis: the role and status of hepatoprotective anti-inflammatory drugs in the prevention and treatment of NAFLD is still controversial, and there is not enough evidence to recommend the routine use of such drugs in patients with NAFLD/NASH under the premise of basic treatment, hepatoprotective anti-inflammatory drugs can be used as adjuvant therapy mainly in the following cases (III): (1) patients with NASH diagnosed by liver histology; (2) (2) patients with clinical features, laboratory changes and imaging tests suggesting the possibility of significant liver injury and/or progressive liver fibrosis, such as NAFLD patients with increased serum aminotransferases, metabolic syndrome and type 2 diabetes mellitus; (3) patients whose proposed use of other drugs interferes with the implementation of the basic treatment plan because of the possibility of inducing liver injury, or those with increased serum aminotransferases during the course of basic treatment; (4) patients with a combination of hepatophilic (4) Combination of hepatophilic virus infection or other liver diseases. It is recommended that l to 2 Chinese and Western drugs such as polyenyl phosphatidylcholine, silymarin (bin), glycyrrhetinic acid preparations, bicyclic alcohol, vitamin E, ursodeoxycholic acid, S-adenosylmethionine and reduced glutathione be used reasonably according to the disease activity and stage as well as drug efficacy and price (II. 1, II-2, II-3), and the course of treatment usually requires more than 6 to 12 months (III).